evista การใช้
- One panel member called Evista " estrogen light ."
- For that reason, the FDA approved Evista only for osteoporosis.
- Evista's now show only that it builds bone.
- The news gave investors hope that the outlook for Evista would brighten.
- Evista's " side effect profile is very favorable,"
- Some analysts see estimates for Evista sales as overblown.
- Also known as Evista, raloxifene is considered to have fewer side effects.
- Evista generated $ 665 million in sales last year.
- "That's what has happened to Lilly with Evista ."
- Evista : Helps restore estrogen and bone loss.
- The researchers concluded that Evista did not have an overall effect on cognitive function.
- Lilly expects to start sales of a similar drug, Evista, in early 1998.
- Lilly is expected to file this summer for FDA approval for Evista for prevention of osteoporosis.
- Evista prevented bone loss, measured in the spine and hip, according to the study.
- Still, he said Evista has huge potential sales in the largely untapped osteoporosis treatment market.
- Panel members said Evista didn't appear as effective as Premarin in building bone density.
- Evista sales might not have to carry as much slack as some analysts expect, however.
- Raloxifene is marketed by Eli Lilly & Co . under the trade name Evista.
- Evista : www . evista . com
- Evista : www . evista . com
- ตัวอย่างการใช้เพิ่มเติม: 1 2 3